https://www.pharmaradar360.com/article/6b17b0dc93b98773Pharma Surgeen2026-05-14T11:32:28.000ZBiogen's anti-tau Alzheimer's drug misses Phase 2 goal, but will move to pivotal studyhttps://www.pharmaradar360.com/article/a59159619c2a23bfPharma Surgeen2026-05-14T11:30:00.000ZKFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitorhttps://www.pharmaradar360.com/article/e9110d9f8d781527Pharma Surgeen2026-05-14T11:16:56.000ZBoletín sobre Seguridad de Medicamentos de Uso Humano. Marzo de 2026https://www.pharmaradar360.com/article/511bf182aa23b468Pharma Surgeen2026-05-14T11:00:17.000ZRegenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalhttps://www.pharmaradar360.com/article/bd8941ecef5ab71cPharma Surgeen2026-05-14T11:00:00.000ZTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumabhttps://www.pharmaradar360.com/article/6fa75b549a23ca12Pharma Surgeen2026-05-14T11:00:00.000ZCanada nabs time on Extremely Large Telescope with groundbreaking instrument investmenthttps://www.pharmaradar360.com/article/8c37ca7058d15441Pharma Surgeen2026-05-14T11:00:00.000ZLilly and UNICEF collaborate to give millions of children a healthier starthttps://www.pharmaradar360.com/article/87fd130533d9037fPharma Surgeen2026-05-14T10:35:10.000ZZydus to acquire Assertio in $166m dealhttps://www.pharmaradar360.com/article/bbb689d5fe14b5c1Pharma Surgeen2026-05-14T10:31:51.000ZBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclextahttps://www.pharmaradar360.com/article/c3de1aa3e383a5e0Pharma Surgeen2026-05-14T10:30:00.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/dccf20beaf9ecd41Pharma Surgeen2026-05-14T10:30:00.000ZHenry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growthhttps://www.pharmaradar360.com/article/f2fea7eda8823b5bPharma Surgeen2026-05-14T10:12:14.000ZUniversities key to SA’s energy transition, Ramokgopa tells SUhttps://www.pharmaradar360.com/article/d8051d51856f357cPharma Surgeen2026-05-14T10:11:11.000ZΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΑΠΡΙΛΙΟΥ 2026https://www.pharmaradar360.com/article/c77d214d5ba1ec09Pharma Surgeen2026-05-14T10:05:07.000ZReunión del Comité de Medicamentos de Uso Humano de mayo de 2026https://www.pharmaradar360.com/article/7a15d857b7257fb6Pharma Surgeen2026-05-14T10:00:00.000ZHow Misinformation Impacts Evidence-Based Sciencehttps://www.pharmaradar360.com/article/f082fd4cfe2ce586Pharma Surgeen2026-05-14T10:00:00.000Z25 Years of Lessons Learned: Q&A with Ketan Mehtahttps://www.pharmaradar360.com/article/fb59c13edfb690f0Pharma Surgeen2026-05-14T09:59:22.000ZOntozry (cenobamate): Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/09e2bd1a6249ac8bPharma Surgeen2026-05-14T09:59:11.000ZClass 4 Medicines Defect Notification: Fresenius Medical Care Deutschland GmbH, balance 2.3% glucose, 1.25 mmol/l calcium, solution for peritoneal dialysis, EL(26)A/24https://www.pharmaradar360.com/article/1d078c455d2ef0c3Pharma Surgeen2026-05-14T09:39:15.000ZQuartzBio secures Eir Partners investment for trial intelligence platformhttps://www.pharmaradar360.com/article/3a026fa9dd18b4eaPharma Surgeen2026-05-14T09:00:42.000ZUK’s largest independent gambling harms research centre launcheshttps://www.pharmaradar360.com/article/921e5f64e6e9fec4Pharma Surgeen2026-05-14T09:00:00.000ZPrior heart attack linked to faster declines in thinking and memory skillshttps://www.pharmaradar360.com/article/c7996c78b7210a6ePharma Surgeen2026-05-14T08:56:07.000ZOsel and partners launch Phase IIb FLIP-2 trial of Lactin-Vhttps://www.pharmaradar360.com/article/763821b29100e1eaPharma Surgeen2026-05-14T08:51:22.000ZPfizer receives EC approval for Hympavzi to treat haemophiliahttps://www.pharmaradar360.com/article/88811b599f2ea699Pharma Surgeen2026-05-14T08:32:46.000ZVisiting St Thomas' Hospital on Saturday 16 Mayhttps://www.pharmaradar360.com/article/84d6977cac80940bPharma Surgeen2026-05-14T08:30:00.000ZThe Clínic promotes sustainable dialysis with a 22% reduction in CO2 emissionshttps://www.pharmaradar360.com/article/491f82c4ebbad4e9Pharma Surgeen2026-05-14T08:24:39.000ZCountries compete to reform trials in a bid to attract global sponsorshttps://www.pharmaradar360.com/article/aec6b1cf28009a5cPharma Surgeen2026-05-14T08:21:48.000ZObama advisor to speak on AI and democracyhttps://www.pharmaradar360.com/article/90ad1bd91237e8c1Pharma Surgeen2026-05-14T08:21:14.000ZDevelopments in sepsis, antimicrobial resistance, antifungals, and immunotherapieshttps://www.pharmaradar360.com/article/fe31805b7d87a053Pharma Surgeen2026-05-14T08:06:09.000ZDisruptions may occur when sending e-mails to State Agency of Medicines contactshttps://www.pharmaradar360.com/article/e1999d2cf1331e60Pharma Surgeen2026-05-14T08:05:35.000ZTrends in Renal Research: Nephrology’s Shift to Focus and Precisionhttps://www.pharmaradar360.com/article/a823db9d82962a50Pharma Surgeen2026-05-14T08:05:35.000ZTrends in Renal Research: Nephrology’s Shift to Focus and Precisionhttps://www.pharmaradar360.com/article/e56f6f84947acbc2Pharma Surgeen2026-05-14T08:02:51.000ZMaretha Joyce the steady hand behind the sceneshttps://www.pharmaradar360.com/article/e4813e2bc5cea7aePharma Surgeen2026-05-14T08:00:08.000ZThree new Trustees join Board of Quadram Institute Biosciencehttps://www.pharmaradar360.com/article/db3ce5b0d57c27f3Pharma Surgeen2026-05-14T08:00:07.000ZJornada sobre CHESSMEN, la acción conjunta de problemas de suministro de medicamentoshttps://www.pharmaradar360.com/article/b62b0e848a5785f3Pharma Surgeen2026-05-14T08:00:00.000ZLa AEMPS organiza una jornada sobre la acción conjunta CHESSMENhttps://www.pharmaradar360.com/article/e8fa5f3061548bfcPharma Surgeen2026-05-14T07:31:06.000ZNAFDAC becomes the 24th member of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Usehttps://www.pharmaradar360.com/article/c52e5dec5706aeb0Pharma Surgeen2026-05-14T07:16:04.000ZRadiologist-AI combo has highest potential to improve pulmonary embolism detection, experts chargehttps://www.pharmaradar360.com/article/e53af21ec29fc000Pharma Surgeen2026-05-14T07:08:21.000ZSolis Mammography opens 4 new imaging centershttps://www.pharmaradar360.com/article/b6f88c1a37470b05Pharma Surgeen2026-05-14T07:01:43.000Z82% of radiologists and other physicians now employed by corporate entitieshttps://www.pharmaradar360.com/article/9b8fc5ff82cba918Pharma Surgeen2026-05-14T07:00:00.000ZDr. Davies highlights med center’s role addressing hantavirus outbreakhttps://www.pharmaradar360.com/article/72606d61808e5295Pharma Surgeen2026-05-14T06:58:00.000ZTwo honored with inaugural Staff Advisory Council awardshttps://www.pharmaradar360.com/article/4a5b6e358f77adccPharma Surgeen2026-05-14T06:57:03.000ZPDBe-SIFTS for protein sequence-structure mappinghttps://www.pharmaradar360.com/article/208fd2834beceaeePharma Surgeen2026-05-14T06:56:00.000ZCeremony today to celebrate UNMC’s expansion in Kearneyhttps://www.pharmaradar360.com/article/564c325e958ccd25Pharma Surgeen2026-05-14T06:54:00.000ZHelp boost UNMC’s community engagement effortshttps://www.pharmaradar360.com/article/e40f6e89b69b98f6Pharma Surgeen2026-05-14T06:52:00.000ZUNMC applications will be unavailable Saturdayhttps://www.pharmaradar360.com/article/a1a8066bf4f0eea5Pharma Surgeen2026-05-14T06:50:00.000ZRegenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapyhttps://www.pharmaradar360.com/article/7f8586137d4d44b5Pharma Surgeen2026-05-14T06:35:00.000ZAptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks developmenthttps://www.pharmaradar360.com/article/324d87f00a14ae15Pharma Surgeen2026-05-14T06:30:58.000ZWest Lancashire trust optimises EPR to improve abdomen pathwayhttps://www.pharmaradar360.com/article/5284e730867fbce1Pharma Surgeen2026-05-14T06:30:00.000Zヒト化抗CD20モノクローナル抗体「ガザイバ」特発性ネフローゼ症候群に対して適応拡大申請https://www.pharmaradar360.com/article/5a938dd78fb47bdcPharma Surgeen2026-05-14T06:30:00.000ZFiling of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndromehttps://www.pharmaradar360.com/article/a7cd0e0fb68a80dfPharma Surgeen2026-05-14T06:29:57.000ZFlinders University breaks new ground in Mount Gambierhttps://www.pharmaradar360.com/article/d9737ffa5ad85571Pharma Surgeen2026-05-14T06:00:00.000ZAstellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/98049e3e1e750d8aPharma Surgeen2026-05-14T05:49:52.000ZAesthetics, built from sciencehttps://www.pharmaradar360.com/article/ccbfe204e1d04e51Pharma Surgeen2026-05-14T05:21:15.000ZProviding a cellular ‘all-clear’ signal to resume protein synthesishttps://www.pharmaradar360.com/article/ab2ca25dee0709a0Pharma Surgeen2026-05-14T05:01:06.000ZFrom Data Chaos to Discovery: Building the Data Foundation for AI-Ready Scientific Researchhttps://www.pharmaradar360.com/article/e28c6bac32336bf6Pharma Surgeen2026-05-14T05:00:37.000ZWho are the Japanese? Huge DNA discovery rewrites historyhttps://www.pharmaradar360.com/article/83f703b7964ba821Pharma Surgeen2026-05-14T04:47:47.000ZDazzling gala commemorates Afrikaans dictionary’s centenary and ties with SUhttps://www.pharmaradar360.com/article/fc26317979f6d21dPharma Surgeen2026-05-14T04:09:08.000Z2025年度 ナース・オブ・ザ・イヤー授賞式を執り行いましたhttps://www.pharmaradar360.com/article/eedca02739dcc910Pharma Surgeen2026-05-14T04:08:13.000Z2026年度 第1回東北大学病院脳卒中・心臓病等総合支援センター県民公開講座in大衡村開催のお知らせ（6/23開催）https://www.pharmaradar360.com/article/1d9683b0d97e22d4Pharma Surgeen2026-05-14T03:34:56.000ZWhat Is Clinical Trials Day? Why Technology Helps Research Risehttps://www.pharmaradar360.com/article/9f5e2588b9b2627fPharma Surgeen2026-05-14T02:06:27.000ZPAI-1阻害薬「TM5614」の抗老化効果をヒトで確認－XPRIZE Healthspanセミファイナル臨床試験結果－https://www.pharmaradar360.com/article/f018438f713582bcPharma Surgeen2026-05-14T02:00:00.000ZWegovy and Mounjaro for weight loss not fundedhttps://www.pharmaradar360.com/article/be733b1bc134e0a3Pharma Surgeen2026-05-14T01:07:03.000ZNew psychedelic-like drugs could treat depression without making you triphttps://www.pharmaradar360.com/article/f282505dc65707eaPharma Surgeen2026-05-14T01:00:37.000ZUFRJ inaugura Centro de Livros da China na Faculdade de Letrashttps://www.pharmaradar360.com/article/30fa07b1e018c909Pharma Surgeen2026-05-14T00:00:00.000ZU.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapyhttps://www.pharmaradar360.com/article/82be4303a0e72c4bPharma Surgeen2026-05-14T00:00:00.000ZIntegrated single-cell and spatial transcriptomic profiling in ALS uncovers peripheral-to-central immune infiltration and reprogramminghttps://www.pharmaradar360.com/article/75c682b07ff438a3Pharma Surgeen2026-05-14T00:00:00.000ZSynchronous climbing fiber activity enables instructive signaling for cerebellar learning through modulation of disinhibitory circuitshttps://www.pharmaradar360.com/article/74e217b3f20f6197Pharma Surgeen2026-05-14T00:00:00.000ZAbatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trialhttps://www.pharmaradar360.com/article/968de70749b11faaPharma Surgeen2026-05-14T00:00:00.000ZPerformance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathyhttps://www.pharmaradar360.com/article/0a6a64b3ad1f4eebPharma Surgeen2026-05-14T00:00:00.000ZAdvancing conversational diagnostic AI with multimodal reasoninghttps://www.pharmaradar360.com/article/fc7411df76096d8cPharma Surgeen2026-05-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/37feff17dbd95f24Pharma Surgeen2026-05-14T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/428b30d7736dff33Pharma Surgeen2026-05-14T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/f29f63376a7ce163Pharma Surgeen2026-05-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/fa643f9f4135078bPharma Surgeen2026-05-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/7aab0ac0c139a5a8Pharma Surgeen2026-05-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/36785f37dfcd4a85Pharma Surgeen2026-05-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/20d8c191ab37642ePharma Surgeen2026-05-14T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/6270ec8ed96e3c5fPharma Surgeen2026-05-14T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/febb0e8ac6f26da3Pharma Surgeen2026-05-14T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/26e7a8d979b7eff0Pharma Surgeen2026-05-14T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/66b68dbab3305eb4Pharma Surgeen2026-05-14T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/cc484c65357b6968Pharma Surgeen2026-05-14T00:00:00.000Z6203https://www.pharmaradar360.com/article/b7e57133489b3fb7Pharma Surgeen2026-05-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/f84ca61d613e6c34Pharma Surgeen2026-05-14T00:00:00.000ZGH Research Reports First Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/80c783ee99a18e34Pharma Surgeen2026-05-13T23:38:09.000ZState health authorities investigating radiology group's handling of fatal MRI incidenthttps://www.pharmaradar360.com/article/95128c0201becf26Pharma Surgeen2026-05-13T23:18:47.000ZShoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlookhttps://www.pharmaradar360.com/article/e5f15fd4491de35ePharma Surgeen2026-05-13T22:58:32.000ZSimple measurement from routine X-rays accurately predicts post-op lung cancer outcomeshttps://www.pharmaradar360.com/article/506264ddc0fcfe6ePharma Surgeen2026-05-13T22:20:00.000ZSmith Entertainment Group and Intermountain Health Announce Groundbreaking Partnership and Creation of World-Class Sports Performance Center Co-located with Utah Jazz and Utah Mammoth Practice Facilitieshttps://www.pharmaradar360.com/article/ee4a4239ef082e4bPharma Surgeen2026-05-13T21:57:41.000ZVisualizing Receptor Transport Within Neurons via Transcytosishttps://www.pharmaradar360.com/article/0523acfe7df18242Pharma Surgeen2026-05-13T21:52:24.000ZChallenging negative stereotypes and embracing strengths associated with aginghttps://www.pharmaradar360.com/article/0d8664adf972f5abPharma Surgeen2026-05-13T21:19:03.000ZCytokine-Driven Divergence Between Allogeneic CAR-T Platformshttps://www.pharmaradar360.com/article/432475f9ef3c966dPharma Surgeen2026-05-13T21:13:10.000ZFinger Lakes Community Rallies Around New Opportunities at 2026 Tour de Cure Diabetes Fundraiserhttps://www.pharmaradar360.com/article/ce7339b7dbd71c0cPharma Surgeen2026-05-13T21:00:00.000ZAptose Reports First Quarter 2026 Resultshttps://www.pharmaradar360.com/article/323365cd69861adbPharma Surgeen2026-05-13T20:55:32.000ZPrincipales Logros Consejo Directivo y JVPS período 2024-2026https://www.pharmaradar360.com/article/94ada742e62ec3a1Pharma Surgeen2026-05-13T20:34:52.000ZBMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaborationhttps://www.pharmaradar360.com/article/6132b23d813b46fcPharma Surgeen2026-05-13T20:17:48.000ZBecker’s Highlights Improved Workplace Safety at Scrippshttps://www.pharmaradar360.com/article/94d362aa299ae23dPharma Surgeen2026-05-13T20:05:00.000ZTalphera Announces First Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/7784751b02f266cePharma Surgeen2026-05-13T20:05:00.000ZVivani Medical Reports First Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/b11d3d299fbec3c2Pharma Surgeen2026-05-13T20:02:00.000ZAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Updatehttps://www.pharmaradar360.com/article/8ad00941e67df021Pharma Surgeen2026-05-13T20:00:19.000ZASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Endshttps://www.pharmaradar360.com/article/401e57050b49f4f8Pharma Surgeen2026-05-13T19:59:00.000ZHelmsley Charitable Trust destina $20 millones para que Intermountain Health expanda los servicios de salud conductual pediátrica en Nevadahttps://www.pharmaradar360.com/article/6cf01ba81109d1acPharma Surgeen2026-05-13T19:58:09.000ZThe condition PCOS has a new name. Here’s what the change means for patientshttps://www.pharmaradar360.com/article/7bff82123258f5dbPharma Surgeen2026-05-13T19:57:10.000ZWhat a Student-Centered University Really Looks Likehttps://www.pharmaradar360.com/article/e0e39fa6774164a6Pharma Surgeen2026-05-13T19:55:59.000ZMichele Tafoya has the support of the national GOP, but winning over state activists is a challengehttps://www.pharmaradar360.com/article/c950bac32a73b296Pharma Surgeen2026-05-13T19:52:38.000ZSynthesizing a Natural Sunscreen and Antioxidant in E. colihttps://www.pharmaradar360.com/article/372f105dceb91e11Pharma Surgeen2026-05-13T19:44:58.000ZMaster Protocols in Oncology: A Biostatistics Execution Perspectivehttps://www.pharmaradar360.com/article/d8fd4553d9ab3f4aPharma Surgeen2026-05-13T19:44:58.000ZMaster Protocols in Oncology: A Biostatistics Execution Perspectivehttps://www.pharmaradar360.com/article/86aa97dfc433ee28Pharma Surgeen2026-05-13T19:42:48.000ZHelmsley Charitable Trust Commits $20 Million to Intermountain Health to Expand Pediatric Behavioral Health Services in Nevadahttps://www.pharmaradar360.com/article/14c6cb8aac7136e3Pharma Surgeen2026-05-13T19:22:00.000ZSalesforce, Echo Health Ventures back Optura's $17.5M series A to track AI performancehttps://www.pharmaradar360.com/article/ba76526b1f5adeb8Pharma Surgeen2026-05-13T18:50:53.000ZAfter an apparent cure, a gene editing company struggles to repeat the magichttps://www.pharmaradar360.com/article/971e0e5b456e1ed5Pharma Surgeen2026-05-13T18:45:21.000ZApexGO: AI-Driven Approach to Faster Antibiotic Discoveryhttps://www.pharmaradar360.com/article/cd3a5ccb3ed6536ePharma Surgeen2026-05-13T18:36:06.000ZTakeda to target 4,500 jobs as incoming CEO continues restructuringhttps://www.pharmaradar360.com/article/b67bce772e513971Pharma Surgeen2026-05-13T18:27:36.000ZCrossing Paths: How the National MPS Society Reaches Families Where They Arehttps://www.pharmaradar360.com/article/eb53bc4eb3bc2e3cPharma Surgeen2026-05-13T18:26:42.000ZPharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanuhttps://www.pharmaradar360.com/article/72f58385c70429dfPharma Surgeen2026-05-13T18:24:07.000ZANMAT impulsa la cooperación regulatoria regional y la actualización normativa dentro del Mercosurhttps://www.pharmaradar360.com/article/659173d549c60366Pharma Surgeen2026-05-13T18:00:00.000ZThe Questions You Couldn’t Ask in Time: How Agentic AI Accelerates Market Entryhttps://www.pharmaradar360.com/article/6d1760f3e973f95ePharma Surgeen2026-05-13T17:46:51.000ZValneva to cut up to 15% of jobs as reduced travel hits vaccine demandhttps://www.pharmaradar360.com/article/953b0e37619fc7baPharma Surgeen2026-05-13T17:25:00.000ZCMS to withhold $1.3B in Medicaid funds from California, puts state officials on notice about fraudhttps://www.pharmaradar360.com/article/9f28cd44e7407c25Pharma Surgeen2026-05-13T17:00:07.000ZWhy AI Alone Isn’t Enough for Oligonucleotide Discoveryhttps://www.pharmaradar360.com/article/03915122c22e889fPharma Surgeen2026-05-13T16:39:44.000ZCellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancerhttps://www.pharmaradar360.com/article/0ce5f53862a7705cPharma Surgeen2026-05-13T16:34:18.000ZThe American Diabetes Association Recognized for Workplace Wellnesshttps://www.pharmaradar360.com/article/d133fa6d504a88eePharma Surgeen2026-05-13T16:32:56.000ZBuilding Successful Viral Vector Production Processeshttps://www.pharmaradar360.com/article/9b95dc26bc17ef9ePharma Surgeen2026-05-13T16:23:29.000ZGlobal COVID-19 Trackerhttps://www.pharmaradar360.com/article/1258741a164ad5a7Pharma Surgeen2026-05-13T16:22:00.000ZBeOne's Venclexta challenger Beqalzi nets FDA approval as first BCL-2 for mantle cell lymphomahttps://www.pharmaradar360.com/article/cc9eaef8c09515a0Pharma Surgeen2026-05-13T16:04:06.000Z2026 elections in Scotland and Wales: a turning point for cancer?https://www.pharmaradar360.com/article/7fe4df189d4005f6Pharma Surgeen2026-05-13T16:01:21.000ZVoxCell BioInnovation & adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platformhttps://www.pharmaradar360.com/article/00c43c9b9bd5bc2bPharma Surgeen2026-05-13T16:00:52.000ZAdopting Creative Chemistry to Optimize Bioprocessing Workflowhttps://www.pharmaradar360.com/article/897dabf6079f9d34Pharma Surgeen2026-05-13T16:00:44.000ZYeast We Can: Cutting Costs by Optimizing Cell-Free Expression Systemshttps://www.pharmaradar360.com/article/b14f172ba7a72987Pharma Surgeen2026-05-13T16:00:29.000ZOperator Protection as Core Design Principle for ADC Bioprocessinghttps://www.pharmaradar360.com/article/fa048afebf1be3ccPharma Surgeen2026-05-13T16:00:00.000ZLife sciences ‘sweet’ opportunity in US-China talkshttps://www.pharmaradar360.com/article/55b5194f15523c28Pharma Surgeen2026-05-13T15:54:00.000ZNew payer-backed ad campaign pushes for No Surprises Act IDR reformhttps://www.pharmaradar360.com/article/591dc05fe2a22e70Pharma Surgeen2026-05-13T15:50:57.000ZScripps Cancer Center Expert Offers Tips to Keep Skin Safehttps://www.pharmaradar360.com/article/ce4657b62c4785daPharma Surgeen2026-05-13T15:36:52.000ZAbeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3https://www.pharmaradar360.com/article/c7f421965090e2b3Pharma Surgeen2026-05-13T15:28:36.000ZVetter Starts Construction of a New Production Site in Germanyhttps://www.pharmaradar360.com/article/bf21efe131b7ae75Pharma Surgeen2026-05-13T14:59:53.000ZLa UNLP realizó una nueva entrega de bicicletas a sus estudianteshttps://www.pharmaradar360.com/article/3a47b61017920671Pharma Surgeen2026-05-13T14:58:08.000ZMaintain Patient Trust: How to Use AI in Lay Summary Developmenthttps://www.pharmaradar360.com/article/8a2577d7ea764e48Pharma Surgeen2026-05-13T14:52:00.000ZDocs more burned out, skeptical of AI than nurses, survey report findshttps://www.pharmaradar360.com/article/829324d503411656Pharma Surgeen2026-05-13T14:46:37.000ZPost-Hoc: Why FDA Commissioner Marty Makary was oustedhttps://www.pharmaradar360.com/article/47a218bc4db3b87bPharma Surgeen2026-05-13T14:42:50.000ZLa AEMPS publica las instrucciones para la utilización de códigos QR en el prospecto y/o etiquetado de los medicamentoshttps://www.pharmaradar360.com/article/fdefdbf1fbe6e09ePharma Surgeen2026-05-13T14:30:46.000ZEconomía circular: en alianza con productores locales, nace el tomate deshidratado de la UNLPhttps://www.pharmaradar360.com/article/28665a7cf2a75211Pharma Surgeen2026-05-13T14:30:10.000ZLa UNLP en un relevamiento inédito en barrios populares de La Plata, Berisso y Ensenadahttps://www.pharmaradar360.com/article/ede14e51d6abc9a1Pharma Surgeen2026-05-13T14:29:59.000ZThis daily habit could lower dementia risk by 35%, scientists sayhttps://www.pharmaradar360.com/article/e20ce4a9642da36cPharma Surgeen2026-05-13T14:25:58.000ZMedicaid Mental Health and Substance Use: Expansion Trends and the Fiscal Pressure Aheadhttps://www.pharmaradar360.com/article/f4219a785d4c8b28Pharma Surgeen2026-05-13T14:25:04.000ZInformation about the criminal offence committed by a former employee of the University of Freiburghttps://www.pharmaradar360.com/article/d4cea4995717851cPharma Surgeen2026-05-13T14:22:48.000Z‘I want to help patients'https://www.pharmaradar360.com/article/25e9033a71cee4a2Pharma Surgeen2026-05-13T14:21:53.000ZTree communities influence food webs in European forest floorshttps://www.pharmaradar360.com/article/c6b45cd2dddbe22dPharma Surgeen2026-05-13T14:10:52.000ZNew findings link common pesticide to early-onset colorectal cancerhttps://www.pharmaradar360.com/article/c8cb09ea796f7ca6Pharma Surgeen2026-05-13T14:00:00.000ZBeing an Expert Is About More Than Just Knowing the Answershttps://www.pharmaradar360.com/article/bfd21d73a0a36177Pharma Surgeen2026-05-13T14:00:00.000ZAcoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapyhttps://www.pharmaradar360.com/article/017d985d2a45cf2cPharma Surgeen2026-05-13T14:00:00.000ZPremotor cortex hemodynamic responses primarily reflect perceptual rather than specific motor aspects of decision makinghttps://www.pharmaradar360.com/article/73f7e93586d69714Pharma Surgeen2026-05-13T13:59:17.000ZUC Irvine researchers invent a wearable, bioelectronic sweat sensor for long-term health monitoringhttps://www.pharmaradar360.com/article/d08aceb03250818fPharma Surgeen2026-05-13T13:55:01.000ZBiventricular repair linked to better outcomes in superior-inferior ventricles treatmenthttps://www.pharmaradar360.com/article/9fa2b408cfc48b21Pharma Surgeen2026-05-13T13:53:00.000ZAs Trump arrives in China, Big Pharma CEOs are notably absenthttps://www.pharmaradar360.com/article/b2ce00edff7095b0Pharma Surgeen2026-05-13T13:52:51.000ZECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body compositionhttps://www.pharmaradar360.com/article/aa8957fa1936e674Pharma Surgeen2026-05-13T13:47:30.000ZEli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectableshttps://www.pharmaradar360.com/article/2373546ebee97637Pharma Surgeen2026-05-13T13:43:26.000ZOrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development & Manufacturing Organizationhttps://www.pharmaradar360.com/article/320a2610a8796e5bPharma Surgeen2026-05-13T13:39:15.000ZReformulation, Resilience, and the Race for Relevance in 2026https://www.pharmaradar360.com/article/7880adffa4de6ae5Pharma Surgeen2026-05-13T13:38:22.000ZNorstellaLinQ: Identify obesity treatment opportunity before the market doeshttps://www.pharmaradar360.com/article/b0dda03f9a96593ePharma Surgeen2026-05-13T13:35:00.000ZOrganspende – eine Frage des Alters?https://www.pharmaradar360.com/article/aa755a46ed4e80caPharma Surgeen2026-05-13T13:30:48.000ZBehind Galapagos’ transformation into Lakefront Biotherapeuticshttps://www.pharmaradar360.com/article/6a56721f2671ca5aPharma Surgeen2026-05-13T13:30:04.000ZSCI-TIF community gathers for 4th Annual Networking Dinnerhttps://www.pharmaradar360.com/article/2a56fda4f1e8e2f9Pharma Surgeen2026-05-13T13:29:51.000ZGirls Play Global thanks to this Tar Heelhttps://www.pharmaradar360.com/article/a2a840ccbb6a61cePharma Surgeen2026-05-13T13:21:12.000ZRigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanuhttps://www.pharmaradar360.com/article/cf4f9abfa50af692Pharma Surgeen2026-05-13T13:18:00.000ZIcon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilitieshttps://www.pharmaradar360.com/article/0399b812be38518bPharma Surgeen2026-05-13T13:14:59.000ZInnovative heart failure treatment proves transformative for patientshttps://www.pharmaradar360.com/article/bb963c23301576a6Pharma Surgeen2026-05-13T13:07:00.000ZCMS pauses hospice, home health Medicare enrollments in fraud crackdownhttps://www.pharmaradar360.com/article/e98410d686e7ebc7Pharma Surgeen2026-05-13T13:00:00.000ZWhat investors now expect from AI biotech companieshttps://www.pharmaradar360.com/article/44ffa98e6c300711Pharma Surgeen2026-05-13T12:59:37.000ZDiretores e decanos debatem protocolo institucional para situações de violência urbanahttps://www.pharmaradar360.com/article/bbb89beddd57c906Pharma Surgeen2026-05-13T12:57:05.000ZTerumo Blood & Cell Technologies & Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturinghttps://www.pharmaradar360.com/article/46982412ddb77920Pharma Surgeen2026-05-13T12:46:14.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/ef845f38b36f9b6bPharma Surgeen2026-05-13T12:45:11.000ZThe Pharma Days 2026https://www.pharmaradar360.com/article/a9e28e18bed6d05bPharma Surgeen2026-05-13T12:44:48.000ZZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitorhttps://www.pharmaradar360.com/article/d61a0ccd9b85693bPharma Surgeen2026-05-13T12:43:11.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/b04c626263a2303bPharma Surgeen2026-05-13T12:38:36.000ZMedical devices: conformity assessment and the UKCA markhttps://www.pharmaradar360.com/article/f288ba6278c0ac03Pharma Surgeen2026-05-13T12:30:59.000ZHarrogate and District launches phase two of Nervecentre EPRhttps://www.pharmaradar360.com/article/1e4baa8f920190b5Pharma Surgeen2026-05-13T12:25:00.000ZPharmaceutical Traceability & Supply Chain Monitoringhttps://www.pharmaradar360.com/article/bfd39b494e82a242Pharma Surgeen2026-05-13T12:24:51.000ZSCiLL to become independent academic unithttps://www.pharmaradar360.com/article/15b802e0d4093001Pharma Surgeen2026-05-13T12:17:06.000ZStrengthening the knowledge base for EU climate policyhttps://www.pharmaradar360.com/article/5c5ce154c5c78bdePharma Surgeen2026-05-13T12:06:11.000ZPresentation of #DHH26 Hackathon projects on 29rd May 2026https://www.pharmaradar360.com/article/a423f19675f53a91Pharma Surgeen2026-05-13T12:00:56.000ZTessera reveals strongest data yet for in vivo sickle cell therapyhttps://www.pharmaradar360.com/article/eab3691dd6cddaf3Pharma Surgeen2026-05-13T12:00:00.000ZICON expands US early phase research capabilitieshttps://www.pharmaradar360.com/article/9e00b8ee1c3e2d47Pharma Surgeen2026-05-13T12:00:00.000ZCharles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutionshttps://www.pharmaradar360.com/article/5db6def23c5c31a6Pharma Surgeen2026-05-13T11:56:03.000ZJellinek Dialogues: Power Conflicts in Researchhttps://www.pharmaradar360.com/article/9e7deb126e28d07aPharma Surgeen2026-05-13T11:54:28.000ZAcreditados | Acreditación de Proyectos I+D y PPID 2026https://www.pharmaradar360.com/article/bdb669df1802d9f4Pharma Surgeen2026-05-13T11:30:00.000ZAbeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Updatehttps://www.pharmaradar360.com/article/778788e8e0b81ce3Pharma Surgeen2026-05-13T11:24:00.000ZNYU Langone Health says it received grand jury subpoena over gender-affirming carehttps://www.pharmaradar360.com/article/8718035ae9ee1941Pharma Surgeen2026-05-13T11:22:31.000ZAlexander von Humboldt professorship for Simon Elsässer – “You can think of it as a kind of cellular memory”https://www.pharmaradar360.com/article/8b68224d06048519Pharma Surgeen2026-05-13T11:22:00.000ZMerck KGaA looks to M&A to bolster its 'rather slim' pipelinehttps://www.pharmaradar360.com/article/1835b415a4acd9b0Pharma Surgeen2026-05-13T11:21:00.000ZTakeda, slimming down for 'new era,' plots 4,500 layoffs in latest restructuring drivehttps://www.pharmaradar360.com/article/040b30097badf46dPharma Surgeen2026-05-13T11:18:04.000ZResearch Sheds Light on Modern Myth Retellingshttps://www.pharmaradar360.com/article/16bc52f00320aa49Pharma Surgeen2026-05-13T11:14:27.000Z6 Fragen an Prof. Carolin Lerchenmüller zur Frauen Herzsprechstundehttps://www.pharmaradar360.com/article/25f5fa899e4cd670Pharma Surgeen2026-05-13T11:13:00.000ZBeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions'https://www.pharmaradar360.com/article/38f98ad96c358d5fPharma Surgeen2026-05-13T11:11:00.000ZHealth systems are exploring AI-powered cardiac risk screening. New CMS reimbursement could unlock a business case for ithttps://www.pharmaradar360.com/article/085dd95496093feaPharma Surgeen2026-05-13T11:05:00.000ZMost mental health practitioners satisfied with work, financially stable, SimplePractice findshttps://www.pharmaradar360.com/article/69ed610c08fb71ebPharma Surgeen2026-05-13T11:01:36.000ZMerck KGaA's clients are stockpiling due to Iran war, supporting guidance boosthttps://www.pharmaradar360.com/article/dd746bd14476df37Pharma Surgeen2026-05-13T11:01:29.000ZΑνάκληση των κωδικών του συνημμένου πίνακα, του Ιατροτεχνολογικού προϊόντος SplashWire Hydrophilic Steerable Guide Wire, (Υδρόφιλο κατευθυνόμενο σύρμα οδηγού SplashWire)https://www.pharmaradar360.com/article/94b0d8f6fc4b720bPharma Surgeen2026-05-13T11:00:00.000ZGhost of long-extinct ancestor lives on in people todayhttps://www.pharmaradar360.com/article/9ed772270f11f632Pharma Surgeen2026-05-13T10:54:48.000ZMarcha federal por la Universidad Públicahttps://www.pharmaradar360.com/article/05fc4a69fddc98c7Pharma Surgeen2026-05-13T10:51:53.000ZInternationaler Tag der Pflegenden 2026 am UKHDhttps://www.pharmaradar360.com/article/b9b1cd7efdb8eb0fPharma Surgeen2026-05-13T10:51:00.000ZNovo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifieshttps://www.pharmaradar360.com/article/b3824692d5b1a202Pharma Surgeen2026-05-13T10:47:44.000ZAcne in estate: come averne curahttps://www.pharmaradar360.com/article/b8eee50705b58146Pharma Surgeen2026-05-13T10:43:35.000ZMedicines Pipeline datahttps://www.pharmaradar360.com/article/ffdd2e898c9c05b2Pharma Surgeen2026-05-13T10:38:14.000ZFIMM Genomics Eventshttps://www.pharmaradar360.com/article/48fb9e8833757d92Pharma Surgeen2026-05-13T10:37:33.000ZNovo Nordisk’s high-dose Wegovy touts near 28% weight loss in early respondershttps://www.pharmaradar360.com/article/8f32da17e7b07f79Pharma Surgeen2026-05-13T10:35:00.000ZFluffy ice could imperil spacecraft landings on ocean moonshttps://www.pharmaradar360.com/article/445238a9f892e27dPharma Surgeen2026-05-13T10:35:00.000ZHaleon tackles sports injuries with latest soccer playhttps://www.pharmaradar360.com/article/4166695ccb03232ePharma Surgeen2026-05-13T10:33:20.000ZEU advances plans to reduce reliance on drug importshttps://www.pharmaradar360.com/article/ea1fd28128e88b6cPharma Surgeen2026-05-13T10:29:31.000ZSimultaneous Tricuspid Valve Replacement and Left Bundle Branch Area Pacing With Surgical Lead Refixationhttps://www.pharmaradar360.com/article/17fab6530971dba2Pharma Surgeen2026-05-13T10:23:33.000ZEnterprise’s Phase II trial of ETD001 meets primary endpoint in pwCFhttps://www.pharmaradar360.com/article/7e07a3ae743169e2Pharma Surgeen2026-05-13T10:21:26.000ZCosa sono e a cosa servono le paratiroidi?https://www.pharmaradar360.com/article/bcce517ba0243581Pharma Surgeen2026-05-13T10:20:07.000ZLeft Atrial Appendage Thrombus/Sludge and Flow Velocity in Patients With Atrial Fibrillation and Low CHA2DS2‐VASc Scoreshttps://www.pharmaradar360.com/article/af3f2b169a174550Pharma Surgeen2026-05-13T10:17:21.000ZZero Fluoroscopy Catheter Ablation of Accessory Pathways and AV Nodal Re‐Entry Tachycardia: A Single Institution Studyhttps://www.pharmaradar360.com/article/e773e86254f89527Pharma Surgeen2026-05-13T10:14:57.000ZUAE approves AstraZeneca’s Baxfendy for hypertensionhttps://www.pharmaradar360.com/article/36969b1503ec5e71Pharma Surgeen2026-05-13T10:09:38.000ZMedical devices: ask for a regulatory advice meeting from the MHRAhttps://www.pharmaradar360.com/article/1b3628b5023e8bdcPharma Surgeen2026-05-13T10:02:47.000ZZymeworks Announces Participation in Upcoming Investor Conferenceshttps://www.pharmaradar360.com/article/f264068852a10666Pharma Surgeen2026-05-13T10:00:55.000ZLa AEMPS informa de un riesgo en los paquetes de baterías Zinc-Aire M de los procesadores de sonido de Advanced Bionicshttps://www.pharmaradar360.com/article/a507e68d883ef659Pharma Surgeen2026-05-13T10:00:32.000ZHealth innovation minister Zubir Ahmed resignshttps://www.pharmaradar360.com/article/28e69735c05df1a2Pharma Surgeen2026-05-13T10:00:00.000ZThe Risks of Conflating Science with Politicshttps://www.pharmaradar360.com/article/4b6aa3b1624c5e3fPharma Surgeen2026-05-13T10:00:00.000ZDeveloping New Therapies Across Multiple Regulatory Landscapeshttps://www.pharmaradar360.com/article/b8f4fcb251bcd285Pharma Surgeen2026-05-13T09:44:16.000ZNHSGGC highlights blueprint to improve access to local healthcare serviceshttps://www.pharmaradar360.com/article/8640740a31c51048Pharma Surgeen2026-05-13T09:36:00.000ZWith $1B Novo deal and diabetes ambitions undimmed, Lexicon is in ‘good shape to go crazy’https://www.pharmaradar360.com/article/07d3a53ab9a7dde2Pharma Surgeen2026-05-13T09:35:48.000ZNext generation of Nightingales honoured with unique professional awardhttps://www.pharmaradar360.com/article/b7d723a2a5711c06Pharma Surgeen2026-05-13T09:25:08.000ZKahimmune Therapeutics signe un accord de collaboration scientifique avec Gustave Roussyhttps://www.pharmaradar360.com/article/2702e754e0cd8703Pharma Surgeen2026-05-13T09:16:00.000ZFosun pays $60M for option on AriBio’s phase 3 Alzheimer’s assethttps://www.pharmaradar360.com/article/dce97d04b90196d2Pharma Surgeen2026-05-13T09:00:03.000ZEditing tRNA Genes to Broaden Nonsense Therapeuticshttps://www.pharmaradar360.com/article/2ff5d8db13b6ba1fPharma Surgeen2026-05-13T09:00:03.000ZInflammatory Myopathieshttps://www.pharmaradar360.com/article/4b035f4f19b3bc37Pharma Surgeen2026-05-13T09:00:03.000ZHow Did Race Get Into Lung Testing?https://www.pharmaradar360.com/article/4bb66b150ec46e33Pharma Surgeen2026-05-13T09:00:03.000ZTelitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trialhttps://www.pharmaradar360.com/article/e89642d0ca873931Pharma Surgeen2026-05-13T09:00:03.000ZEndovascular Treatment of Medium-Vessel-Occlusion Strokeshttps://www.pharmaradar360.com/article/86ce4a7a8ecdebbdPharma Surgeen2026-05-13T09:00:03.000ZEnsitrelvir for Covid-19 Postexposure Prophylaxis in Household Contactshttps://www.pharmaradar360.com/article/1cdb743854c152eePharma Surgeen2026-05-13T09:00:03.000ZCentral Retinal-Vein Occlusionhttps://www.pharmaradar360.com/article/e235f59d683b6157Pharma Surgeen2026-05-13T09:00:03.000ZInhalation Injury from House Fire Smokehttps://www.pharmaradar360.com/article/31139fc6d67869d1Pharma Surgeen2026-05-13T09:00:03.000ZA Phase 3 Trial of Brepocitinib in Dermatomyositishttps://www.pharmaradar360.com/article/1dbbb85bc2b9f5faPharma Surgeen2026-05-13T09:00:03.000ZEndovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Populationhttps://www.pharmaradar360.com/article/785324a324601797Pharma Surgeen2026-05-13T09:00:03.000ZCase 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemiahttps://www.pharmaradar360.com/article/da83666f86af67daPharma Surgeen2026-05-13T09:00:03.000ZCabotegravir plus Rilpivirine for Persons with HIV and Adherence Challengeshttps://www.pharmaradar360.com/article/543ff4e4ba8d057aPharma Surgeen2026-05-13T09:00:03.000ZTherapy for Atrial Fibrillation in Patients with Drug-Eluting Stentshttps://www.pharmaradar360.com/article/da3ab8c9eb99ed5aPharma Surgeen2026-05-13T09:00:03.000ZTargeting CD20 versus APRIL or BAFF and APRIL for IgA Nephropathyhttps://www.pharmaradar360.com/article/ffe7cb19764eb9b3Pharma Surgeen2026-05-13T09:00:03.000ZThe Inherited Basis of Coronary Artery Diseasehttps://www.pharmaradar360.com/article/db7bec3bdd89d793Pharma Surgeen2026-05-13T09:00:03.000ZCurrent Causes of Death among Children and Adolescents in the United Stateshttps://www.pharmaradar360.com/article/1c0f9e5a77e281f3Pharma Surgeen2026-05-13T09:00:03.000ZDulaglutide-Associated Choroidal Lymphoid Hyperplasiahttps://www.pharmaradar360.com/article/ea938a6faca95d7cPharma Surgeen2026-05-13T09:00:00.000ZTalent, humour and science communication shine at the first “Science on Stage: Research Takes the Stage” monologue competitionhttps://www.pharmaradar360.com/article/99cbf37e8d3a7b4dPharma Surgeen2026-05-13T09:00:00.000ZPerimenopause may offer a “window of opportunity” for heart disease prevention in womenhttps://www.pharmaradar360.com/article/9cdddbeae09f9af5Pharma Surgeen2026-05-13T08:59:51.000ZLa AEMPS informa de la retirada de dos lotes del medicamento veterinario Febrinol SP 650mg/g, polvo para administración en agua de bebida para cerdos de engorde y pollos de engordehttps://www.pharmaradar360.com/article/147e435381dd79f2Pharma Surgeen2026-05-13T08:56:53.000ZFEBRINOL S.P. 650 MG/G POLVO PARA ADMINISTRACION EN AGUA DE BEBIDA PARA CERDOS DE ENGORDE Y POLLOS DE ENGORDE (Nº 1647 ESP)https://www.pharmaradar360.com/article/794135d47a351a5ePharma Surgeen2026-05-13T08:52:09.000Z«Ich analysiere leidenschaftlich gerne Daten.»https://www.pharmaradar360.com/article/70ca39f48c384b7dPharma Surgeen2026-05-13T08:40:36.000ZHarnessing AI for more efficient clinical trialshttps://www.pharmaradar360.com/article/e2a62462a8703c45Pharma Surgeen2026-05-13T08:35:29.000ZPlastische Chirurgie zwischen Social-Media-Filtern und Realitäthttps://www.pharmaradar360.com/article/2d45eaf03aaf7840Pharma Surgeen2026-05-13T08:30:30.000ZStudents and researchers from Erasmus University joined hundreds of women advocating for gender justicehttps://www.pharmaradar360.com/article/a09f21c45bbcc4b4Pharma Surgeen2026-05-13T08:22:00.000ZHumacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implanthttps://www.pharmaradar360.com/article/4db0401c7761f6e3Pharma Surgeen2026-05-13T08:21:00.000Z#RASSEGNASTAMPA. L'algoritmo in corsia: Matteo Stocco ai microfoni di Radio Lombardia per parlare degli utilizzi dell'IA in Policlinico di Milanohttps://www.pharmaradar360.com/article/142b94c35772c21ePharma Surgeen2026-05-13T08:18:00.000ZMedtronic to shutter Santa Rosa plant as it restructures cardiovascular unithttps://www.pharmaradar360.com/article/234b526aaf02f846Pharma Surgeen2026-05-13T08:16:00.000ZTwo researchers from the Nuffield Department of Clinical Neurosciences (NDCN) join global network to unravel the complexity of Parkinson’s diseasehttps://www.pharmaradar360.com/article/bbc7155179299079Pharma Surgeen2026-05-13T08:12:03.000ZAI tools life sciences companieshttps://www.pharmaradar360.com/article/1332ba8f994cf842Pharma Surgeen2026-05-13T08:11:43.000ZAlkermes reports encouraging data from Phase III study of Lumryzhttps://www.pharmaradar360.com/article/68591dddf429e4e4Pharma Surgeen2026-05-13T08:07:33.000ZIsomorphic Labs receives $2.1bn for AI drug developmenthttps://www.pharmaradar360.com/article/3f5b41898f7eb434Pharma Surgeen2026-05-13T08:03:00.000ZTIL therapies: the impact on cancer researchhttps://www.pharmaradar360.com/article/dfc5d6968887428aPharma Surgeen2026-05-13T08:01:16.000ZStudy aims to unlock causes of ME/CFS and Long Covidhttps://www.pharmaradar360.com/article/4a7af8c29846d6f2Pharma Surgeen2026-05-13T07:54:47.000ZAmerican Society for Nutrition Foundation and Novo Nordisk Foundation announce 2026 awardees advancing nutrition and obesity sciencehttps://www.pharmaradar360.com/article/de94ad7aa184b315Pharma Surgeen2026-05-13T07:47:29.000ZPatients are discussing whole-body MRIs on Reddit, presenting opportunity for radiologistshttps://www.pharmaradar360.com/article/0e4f6e6bb8edaf85Pharma Surgeen2026-05-13T07:41:03.000ZLumexa acquires imaging center as part of new joint venture with UPMChttps://www.pharmaradar360.com/article/9be8725303826f54Pharma Surgeen2026-05-13T07:35:11.000ZNovel urine test reduces need for MR imaging, prostate biopsieshttps://www.pharmaradar360.com/article/b0b303f8e96a721aPharma Surgeen2026-05-13T07:16:01.000ZAnti-Gender Trouble Workshop 3/26 with Ulrika Dahl in University of Uppsalahttps://www.pharmaradar360.com/article/5883b72f06b78574Pharma Surgeen2026-05-13T07:00:00.000ZAnatomy lab named in honor of Saxenas’ journey in medicinehttps://www.pharmaradar360.com/article/9216809527a93658Pharma Surgeen2026-05-13T07:00:00.000ZRNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type Ihttps://www.pharmaradar360.com/article/a4d5659f5e8b9992Pharma Surgeen2026-05-13T07:00:00.000ZSensory nerves protect against preclinical tendinopathic changes through FGF1 signalinghttps://www.pharmaradar360.com/article/57729ec30e4b2b06Pharma Surgeen2026-05-13T07:00:00.000ZA platform for near real-time and multiplexed monitoring of cerebrospinal fluid biomarkers and flow in neurocritical carehttps://www.pharmaradar360.com/article/1aa8e298d2398865Pharma Surgeen2026-05-13T07:00:00.000ZuPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell targethttps://www.pharmaradar360.com/article/da9986975c06624bPharma Surgeen2026-05-13T07:00:00.000ZPrime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS+ mouse modelhttps://www.pharmaradar360.com/article/7d6cba1be2415ad2Pharma Surgeen2026-05-13T07:00:00.000ZIn vivo adenine base editing ameliorates Dravet syndrome phenotypes in a mouse modelhttps://www.pharmaradar360.com/article/8cf2a20b9c99c08ePharma Surgeen2026-05-13T07:00:00.000ZNatural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblastshttps://www.pharmaradar360.com/article/8571552498cbb224Pharma Surgeen2026-05-13T07:00:00.000ZAdvancing emphysema care: UC Davis Health offers innovative lung treatmenthttps://www.pharmaradar360.com/article/343f81dd8415b872Pharma Surgeen2026-05-13T06:58:00.000ZScott Ehresman, MD, honored as 2026 Koefoot Award recipienthttps://www.pharmaradar360.com/article/918c7e65d6d0f4bePharma Surgeen2026-05-13T06:56:00.000ZCancer center hosts Midwest Data Partner’s Workshophttps://www.pharmaradar360.com/article/0469e16f9d6818dcPharma Surgeen2026-05-13T06:54:00.000ZGlobal engagement announces International Photo Contest winnershttps://www.pharmaradar360.com/article/434c1c39cdd02ca1Pharma Surgeen2026-05-13T06:52:00.000ZUNMC blood drive scheduled for May 18https://www.pharmaradar360.com/article/72dba2ffe3b76e78Pharma Surgeen2026-05-13T06:47:18.000ZVill du bidra till bättre vård? Bli en levande bok i VGRhttps://www.pharmaradar360.com/article/97aff442292540e4Pharma Surgeen2026-05-13T06:30:03.000ZRepairing EPR data errors could cost NHS at least £13.5m in 2026https://www.pharmaradar360.com/article/997907be5f439160Pharma Surgeen2026-05-13T06:30:00.000ZBoy’s brain tumor tied to gene therapyhttps://www.pharmaradar360.com/article/fbe7b8a39649216cPharma Surgeen2026-05-13T06:26:00.000ZValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccineshttps://www.pharmaradar360.com/article/42bcb58f7b78a5bcPharma Surgeen2026-05-13T06:26:00.000ZValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccineshttps://www.pharmaradar360.com/article/c10b1b23e88af6ffPharma Surgeen2026-05-13T06:23:31.000ZThe Nagoya Protocol: what is it and what scientists should know about compliancehttps://www.pharmaradar360.com/article/939329480d3c6ee5Pharma Surgeen2026-05-13T06:05:49.000ZNotice of Preliminary Results and Investor Presentationhttps://www.pharmaradar360.com/article/262427612cf95399Pharma Surgeen2026-05-13T06:04:22.000ZIssue of Equity and Total Voting Rightshttps://www.pharmaradar360.com/article/7ffb8593e7869476Pharma Surgeen2026-05-13T05:59:00.000ZBilancio di sostenibilità del Policlinico di Milano. La tua opinione per noi conta. Compila il questionario!https://www.pharmaradar360.com/article/c89edbef4a396bd8Pharma Surgeen2026-05-13T05:47:53.000ZScientists discover a mysterious silicone pollutant that may be everywherehttps://www.pharmaradar360.com/article/afeb4345ed343134Pharma Surgeen2026-05-13T05:09:00.000ZTakeda 0 for 4 against nausea and vomiting after axing another assethttps://www.pharmaradar360.com/article/f35487d1135aa21ePharma Surgeen2026-05-13T05:01:08.000Z36 New Products at Bio-IT World 2026https://www.pharmaradar360.com/article/3bdddd8ecd44bf9fPharma Surgeen2026-05-13T04:18:33.000ZYour “um” and pauses could reveal early dementia riskhttps://www.pharmaradar360.com/article/52b448dbb122d2e3Pharma Surgeen2026-05-13T04:00:10.000ZSumitomo Pharma Announces Personnel Changeshttps://www.pharmaradar360.com/article/75b8e5dd7a89eb75Pharma Surgeen2026-05-13T03:27:21.000ZRapid health tests boost patient confidence and understandinghttps://www.pharmaradar360.com/article/d70c2cf83ee1f553Pharma Surgeen2026-05-13T03:10:00.000ZNotice Regarding Result of Share Repurchase through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3), Completion of Share Repurchase and Cancellation of Treasury Shareshttps://www.pharmaradar360.com/article/f27bea3e1c10c7bePharma Surgeen2026-05-13T03:00:00.000Z[SHINSA]Seven English translations of notifications and administrative notices related to pediatric drug development, including the partial revision of “Planning of the Pediatric Drug Development Program during Development of Drugs for Adults”https://www.pharmaradar360.com/article/85f9bda3d2ee2826Pharma Surgeen2026-05-13T02:58:18.000ZWuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Indexhttps://www.pharmaradar360.com/article/dff05a63ce5dc90dPharma Surgeen2026-05-13T02:25:00.000ZGotcha! Odd language mistakes may help identify fake papershttps://www.pharmaradar360.com/article/44e22ea3c3e4d931Pharma Surgeen2026-05-13T02:07:00.000ZAstraZeneca pens agentic AI licensing deal with Owkinhttps://www.pharmaradar360.com/article/c8453dcc90f226cePharma Surgeen2026-05-13T02:00:00.000ZPublic hospitals to save millions on drug-eluting stentshttps://www.pharmaradar360.com/article/977102759ad37d8fPharma Surgeen2026-05-13T02:00:00.000ZConsultation on proposed changes to diabetes medicine criteriahttps://www.pharmaradar360.com/article/b106242c61060257Pharma Surgeen2026-05-13T02:00:00.000ZAgenda for June 2026 Rheumatology Advisory Committee meeting